SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Seattle Biotech
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: keokalani'nui who wrote (31)10/7/2001 10:16:23 PM
From: keokalani'nui  Read Replies (2) of 70
 
Zymogenetics/Celltech Phase II Results for platelet-derived growth factor receptor antibody CDP 860 are expected to be available by the end of the year. Zymogenetics will use initial public offering funding to develop a blood clotting enzyme and Factor XIII product.

(From 10/1 Pink Sheet)
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News